Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?

Abstract

Although SARS-CoV-2 is considered a lung-tropic virus, severe COVID-19 is not just a viral pulmonary infection, clinically it is a multi-organ pathology with major coagulation abnormalities and thromboembolism events. Recently, antiphospholipid (aPL) antibodies were found increased in a large number of COVID-19 patients. Elevated aPL have been well documented in antiphospholipid syndrome (APS), a systemic autoimmune disorder characterized by recurrent venous or arterial thrombosis and/or obstetrical morbidity. Among treatment regimen of APS, hydroxychloroquine (HCQ) is one of the molecules proposed in the primary prevention of thrombosis and obstetrical morbidity in those patients. Due to its antithrombotic properties documented in APS therapy, HCQ could be considered a good candidate for the prevention of thrombotic events in COVID-19 patients in association with anticoagulant and its repurposing deserves further evaluation.

• Authors: Christian A Devaux, Laurence Camoin-Jau, Jean-Louis Mege, Didier Raoult
• Journal: Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi (J Microbiol Immunol Infect) Vol. 54 Issue 1 Pg. 37-45 (Feb 2021) ISSN: 1995-9133 [Electronic] England
• PMID: 33500211 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2021. Published by Elsevier B.V.

Chemical References

• Antibodies, Antiphospholipid
• Hydroxychloroquine

Topics

• Antibodies, Antiphospholipid (blood)
• Antiphospholipid Syndrome (complications)
• COVID-19 (blood, virology)
• Humans
• Hydroxychloroquine (therapeutic use)
• Morbidity
• SARS-CoV-2 (isolation & purification)
• Thrombosis (blood, prevention & control, virology)
• COVID-19 Drug Treatment